InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
Magnum7419 Free
07/01/21 12:34 PM
profile icon
lesgetrich Free
05/06/21 10:56 AM
profile icon
Taurus69 Free
03/20/21 8:33 PM
profile icon
Taurus69 Free
02/19/21 7:00 PM
profile icon
john1311 Free
02/16/21 7:14 AM
profile icon
SkyPilotUSA Free
02/11/21 9:03 AM
profile icon
Panzer Free
02/04/21 2:08 AM
profile icon
Tanis2476 Free
02/03/21 7:41 PM
profile icon
nunaka Free
02/03/21 6:28 PM
profile icon
Cosa Free
02/03/21 1:00 PM
profile icon
Sooo Waht Free
02/03/21 11:09 AM
profile icon
longboarder7892 Free
02/03/21 10:24 AM
profile icon
Tanis2476 Free
02/03/21 9:27 AM
profile icon
mkendra Free
02/03/21 7:56 AM
profile icon
Taurus69 Free
01/30/21 7:29 PM
profile icon
john1311 Free
01/11/21 7:38 AM
profile icon
Taurus69 Free
01/05/21 10:53 PM
profile icon
Taurus69 Free
12/12/20 6:52 PM
profile icon
Cbdpotential Free
12/07/20 7:55 AM
profile icon
Cosa Free
12/01/20 1:52 PM
profile icon
john1311 Free
11/30/20 9:11 PM
profile icon
Cosa Free
11/24/20 3:16 PM
profile icon
john1311 Free
11/20/20 2:04 AM
profile icon
AllGold818 Free
11/19/20 9:16 PM
profile icon
Cosa Free
11/17/20 3:10 PM
profile icon
Taurus69 Free
11/15/20 3:11 PM
profile icon
Taurus69 Free
11/09/20 4:20 PM
profile icon
whytestocks Free
11/07/20 12:15 PM
profile icon
whytestocks Free
11/03/20 7:19 PM
profile icon
whytestocks Free
11/03/20 2:45 PM
profile icon
whytestocks Free
11/03/20 2:00 PM
profile icon
whytestocks Free
11/03/20 1:45 PM
profile icon
whytestocks Free
11/03/20 1:30 PM
profile icon
whytestocks Free
11/03/20 1:00 PM

GW Pharmaceuticals Plc ADS (GWPH) RSS Feed

Followers
256
Posters
548
Posts (Today)
0
Posts (Total)
5918
Created
04/18/13
Type
Free
Moderators

 
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex which has received Orphan Drug Designation from the FDA for the treatment of Dravet and Lennox-Gastaut syndromes, severe, drug-resistant epilepsy syndromes. GW's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com 
 


GWPH Analyst Stock Ratings:

Citigroup - Target Cut from $97 to $86 - 6/30/14

Morgan Stanley - Overweight - $103 - 5/19/14 (Restated) 4/22/14 (Initiated)

Bank of America - Buy - $110 - 3/11/14

Piper Jaffray - Overweight - $147 - 6/30/14


 
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
GWPH Latest News
  • No Recent News Available for this company!
New Post